Exelixis | EXEL - Zapasy





Zapasy Zmiana Data
Acadia Pharmaceuticals USD 34.67M 5.57M 2025-12
Agios Pharmaceuticals USD 35.09M 2.17M 2026-03
Akebia Therapeutics USD 15.61M 3.03M 2025-12
Amgen USD 6.19B 39M 2026-03
AstraZeneca USD 6.57B 13M 2026-03
Bayer EUR 12.33B 221M 2025-09
BioMarin Pharmaceutical USD 1.27B 25.66M 2026-03
Bristol-Myers Squibb USD 2.76B 66M 2026-03
Cytokinetics USD 0 0 2023-12
Eisai JPY 236.46B 9.14B 2025-09
Eli Lilly USD 14.53B 785M 2026-03
Esperion Therapeutics USD 108.54M 5.93M 2025-09
Exelixis USD 21.69M 5.71M 2025-12
Genmab DKK 13M 1000K 2025-06
Glaxosmithkline GBP 6.12B 46M 2025-09
Incyte USD 115.62M 14.56M 2026-03
Ionis Pharmaceuticals USD 5.56M 4.49M 2026-03
MacroGenics USD 7.91M 840K 2025-12
Merck USD 6.48B 179M 2026-03
Moderna USD 146M 7M 2026-03
Nektar Therapeutics USD 14.46M 1.78M 2024-06
Neurocrine Biosciences USD 64.5M 4.5M 2026-03
Novartis USD 6.29B 17M 2026-03
Pfizer USD 10.67B 13M 2026-03
Puma Biotechnology USD 9.48M 885K 2025-09
Sanofi EUR 22.69B 1.81B 2025-12
Takeda JPY 1.41T 107.71B 2025-12
Ultragenyx Pharmaceutical USD 52M 200K 2025-12